scispace - formally typeset
Search or ask a question
Institution

Teesside University

EducationMiddlesbrough, Middlesbrough, United Kingdom
About: Teesside University is a education organization based out in Middlesbrough, Middlesbrough, United Kingdom. It is known for research contribution in the topics: Population & Context (language use). The organization has 2155 authors who have published 5540 publications receiving 118373 citations. The organization is also known as: University of Teesside.


Papers
More filters
Reference EntryDOI
TL;DR: There is insufficient evidence from randomised controlled trials to determine which method of treatment is the most appropriate for the treatment of acute or chronic Achilles tendinitis.
Abstract: Reason for withdrawal from publication The review was withdrawn, as of Issue 8, 2011, because it is substantially out-of-date.

119 citations

Journal ArticleDOI
TL;DR: Morning-measured ratings of fatigue, sleep quality, and DOMS are clearly more sensitive than HR-derived indices to the daily fluctuations in session load experienced by elite soccer players in a standard in-season week.
Abstract: Purpose:To quantify the mean daily changes in training and match load and any parallel changes in indicators of morningmeasured fatigue across in-season training weeks in elite soccer players.Methods:After each training session and match (TL), session ratings of perceived exertion (s-RPE) were recorded to calculate overall session load (RPE-TL) in 29 English Premier League players from the same team. Morning ratings of fatigue, sleep quality, and delayed-onset muscle soreness (DOMS), as well as submaximal exercise heart rate (HRex), postexercise heart-rate recovery (HRR%), and heart-rate variability (HRV) were recorded before match day and 1, 2, and 4 d postmatch. Data were collected for a median duration of 3 wk (range 1–13) and reduced to a typical weekly cycle including no midweek match and a weekend match day. Data were analyzed using withinsubject linear mixed models.Results:RPE-TL was approximately 600 arbitrary units (AU) (95% confidence interval 546–644) higher on match day than following day (P <...

119 citations

Journal ArticleDOI
TL;DR: The primary outcomes of this review were change in body mass index (BMI), change in weight and adverse events, and all-cause mortality (one suicide in the orlistat intervention group) and socioeconomic effects (not reported).
Abstract: Background Child and adolescent obesity has increased globally, and can be associated with significant short- and long-term health consequences. Objectives To assess the efficacy of drug interventions for the treatment of obesity in children and adolescents. Search methods We searched CENTRAL, MEDLINE, Embase, PubMed (subsets not available on Ovid), LILACS as well as the trial registers ICTRP (WHO) and ClinicalTrials.gov. Searches were undertaken from inception to March 2016. We checked references and applied no language restrictions. Selection criteria We selected randomised controlled trials (RCTs) of pharmacological interventions for treating obesity (licensed and unlicensed for this indication) in children and adolescents (mean age under 18 years) with or without support of family members, with a minimum of three months' pharmacological intervention and six months' follow-up from baseline. We excluded interventions that specifically dealt with the treatment of eating disorders or type 2 diabetes, or included participants with a secondary or syndromic cause of obesity. In addition, we excluded trials which included growth hormone therapies and pregnant participants. Data collection and analysis Two review authors independently assessed trial quality and extracted data following standard Cochrane methodology. Where necessary we contacted authors for additional information. Main results We included 21 trials and identified eight ongoing trials. The included trials evaluated metformin (11 trials), sibutramine (six trials), orlistat (four trials), and one trial arm investigated the combination of metformin and fluoxetine. The ongoing trials evaluated metformin (four trials), topiramate (two trials) and exenatide (two trials). A total of 2484 people participated in the included trials, 1478 participants were randomised to drug intervention and 904 to comparator groups (91 participants took part in two cross-over trials; 11 participants not specified). Eighteen trials used a placebo in the comparator group. Two trials had a cross-over design while the remaining 19 trials were parallel RCTs. The length of the intervention period ranged from 12 weeks to 48 weeks, and the length of follow-up from baseline ranged from six months to 100 weeks. Trials generally had a low risk of bias for random sequence generation, allocation concealment and blinding (participants, personnel and assessors) for subjective and objective outcomes. We judged approximately half of the trials as having a high risk of bias in one or more domain such as selective reporting. The primary outcomes of this review were change in body mass index (BMI), change in weight and adverse events. All 21 trials measured these outcomes. The secondary outcomes were health-related quality of life (only one trial reported results showing no marked differences; very low certainty evidence), body fat distribution (measured in 18 trials), behaviour change (measured in six trials), participants' views of the intervention (not reported), morbidity associated with the intervention (measured in one orlistat trial only reporting more new gallstones following the intervention; very low certainty evidence), all-cause mortality (one suicide in the orlistat intervention group; low certainty evidence) and socioeconomic effects (not reported). Intervention versus comparator for mean difference (MD) in BMI change was -1.3 kg/m2 (95% confidence interval (CI) -1.9 to -0.8; P < 0.00001; 16 trials; 1884 participants; low certainty evidence). When split by drug type, sibutramine, metformin and orlistat all showed reductions in BMI in favour of the intervention. Intervention versus comparator for change in weight showed a MD of -3.9 kg (95% CI -5.9 to -1.9; P < 0.00001; 11 trials; 1180 participants; low certainty evidence). As with BMI, when the trials were split by drug type, sibutramine, metformin and orlistat all showed reductions in weight in favour of the intervention. Five trials reported serious adverse events: 24/878 (2.7%) participants in the intervention groups versus 8/469 (1.7%) participants in the comparator groups (risk ratio (RR) 1.43, 95% CI 0.63 to 3.25; 1347 participants; low certainty evidence). A total 52/1043 (5.0%) participants in the intervention groups versus 17/621 (2.7%) in the comparator groups discontinued the trial because of adverse events (RR 1.45, 95% CI 0.83 to 2.52; 10 trials; 1664 participants; low certainty evidence). The most common adverse events in orlistat and metformin trials were gastrointestinal (such as diarrhoea, mild abdominal pain or discomfort, fatty stools). The most frequent adverse events in sibutramine trials included tachycardia, constipation and hypertension. The single fluoxetine trial reported dry mouth and loose stools. No trial investigated drug treatment for overweight children. Authors' conclusions This systematic review is part of a series of associated Cochrane reviews on interventions for obese children and adolescents and has shown that pharmacological interventions (metformin, sibutramine, orlistat and fluoxetine) may have small effects in reduction in BMI and bodyweight in obese children and adolescents. However, many of these drugs are not licensed for the treatment of obesity in children and adolescents, or have been withdrawn. Trials were generally of low quality with many having a short or no post-intervention follow-up period and high dropout rates (overall dropout of 25%). Future research should focus on conducting trials with sufficient power and long-term follow-up, to ensure the long-term effects of any pharmacological intervention are comprehensively assessed. Adverse events should be reported in a more standardised manner specifying amongst other things the number of participants experiencing at least one adverse event. The requirement of regulatory authorities (US Food and Drug Administration and European Medicines Agency) for trials of all new medications to be used in children and adolescents should drive an increase in the number of high quality trials.

119 citations

Journal ArticleDOI
TL;DR: The idea of intergenerational cultures of worklessness has become influential in UK politics and policy, and was used to explain contemporary worklessness and to justify welfare reforms as mentioned in this paper, but no study has investigated whether such families actually exist.
Abstract: The idea of ‘intergenerational cultures of worklessness’ has become influential in UK politics and policy, and been used to explain contemporary worklessness and to justify welfare reforms. Workless parents are said to pass on to their children attitudes and behaviours which inculcate ‘welfare dependency’. In its strongest version, politicians and welfare practitioners talk confidently of ‘three generations of families where no-one has ever worked’; even though no study, bar this one, has investigated whether such families actually exist. Solid evidence for intergenerational cultures of worklessness is elusive so this study tested the idea via interviews with twenty families in Glasgow and Middlesbrough that had been long-term workless. Theories of intergenerational cultures of worklessness feel like ‘zombie arguments’ – resistant to evidence and social scientific efforts to kill them off. Regardless, the findings of this critical case study are offered as a fresh batch of ammunition with which to try to ...

119 citations

Journal ArticleDOI
TL;DR: This paper draws together and evaluates all currently available methodologies for temperature estimation and vastly advancing the understanding of heat induced changes in bone, thus facilitating a more accurate interpretation.

119 citations


Authors

Showing all 2207 results

NameH-indexPapersCitations
Martin White1962038232387
John Dixon9654336929
Derek K. Jones7637533916
Andrew T. Campbell7534728175
Greg Atkinson7430021725
Alan Burns6342419870
Carolyn Summerbell6319918987
Falko F. Sniehotta6026016194
Roland Lang5914812907
Barry Drust5520910888
Pietro Liò5461320137
Chimay J. Anumba533829445
Mark Taylor5132015426
Victor Chang5039110184
Alan M. Batterham4818313841
Network Information
Related Institutions (5)
Loughborough University
45.1K papers, 1.2M citations

91% related

Deakin University
46.4K papers, 1.1M citations

91% related

RMIT University
82.9K papers, 1.7M citations

91% related

University of Technology, Sydney
46.4K papers, 1M citations

90% related

University of York
56.9K papers, 2.4M citations

89% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202333
202254
2021460
2020439
2019336
2018311